D-Galactosamine (D-galN) is well established as sensitizing mice and other animals to the lethal effects of TNF, specifically, and by several orders of magnitude. Protection by anti-TNF neutralizing antibody is complete, as is (metabolically-based) protection by uridine. Sensitization occurs regardless of the origin of the released TNF, whether it is released from macrophages and/or T-cells. The same is true for the challenging agent which leads to the release of TNF, whether it is endotoxin, a superantigen, lipoprotein, bacterial DNA, or bacteria, either killed or proliferating. Most studies have utilized endotoxin as the challenging agent, and more than 70 agents have been reported to confer protection against LPS and/or TNF challenge in the model. The model has provided new insight regarding modes of protection, including from dexamethasone, which protects against challenge from LPS but not from challenge by TNF. The D-galN lethality model has also been used to test for synergistic behavior between different bacterial components, and to test for lethality when only small amounts of the challenging agent are available (lipid A chemistry).
INTRODUCTION
Galanos and coworkers published two reports, one in 1979 and the other in 1987, that together provided the framework for more than 250 papers from a variety of laboratories using D-galactosamine (D-galN) as a sensitizing agent to TNF-mediated lethality. 1, 2 Included in those initial reports, it was established that administration of D-galN in sufficient dose and at the same time as either LPS or TNF was able to reduce the LD 50 value for LPS and for TNF by several orders of magnitude (see below). Complete protection was afforded by anti-TNF neutralizing antibody establishing that lethality from LPS in this model resulted exclusively from sensitization to the lethal effects of TNF, a particularly seminal finding. 3 Administration of uridine at the time of challenge also completely protected against lethality. It was further established, most definitively from adoptive transfer experiments, that in the D-galN model of LPS lethality, endotoxin responsive macrophages were essential, 1, 2, [4] [5] [6] as is also recognized to be the case for LPS lethality in unsensitized mice. 7 While it is otherwise conceivable that D-galN might sensitize to lethality not only by increasing sensitivity to TNF but also by increasing TNF levels, D-galN does not, of itself, appreciably change circulating levels of TNF following challenge with LPS. 8 Dramatic sensitization to LPS lethality brought on by a simple amino sugar is unique to D-galN. Other chemical agents, such as lead acetate, actinomycin D, among others, are also potent at sensitizing to LPS lethality. [9] [10] [11] [12] D-galN is, nevertheless, unique among these in that it is naturally occurring in the host, and sensitizes in a welldefined time period after its administration, by a welldefined metabolic mechanism, and by a well-defined cytokine mechanism, namely via TNF. With respect to the metabolic mechanism, it has been established that the same enzyme machinery that converts glucose to UDP-glucose and galactose to UDP-galactose also con-verts D-galN to UDP-galN. As a consequence, and at sufficiently high D-galN concentration, uridine becomes sequestered as UDP-galN. In that regard, the enzyme that would otherwise transfer the galactosyl moiety from UDP-galactose to proteins, to form galactosyl proteins and in the process regenerate UTP, lacks sufficient catalytic scope to correspondingly do so to UDP-galN. Consequently, hepatocyte RNA and protein synthesis are severely curtailed until the host is able to resupply UTP. 13 During that interim period, a severe lethal crisis can develop in the presence of LPS or TNF. 1, 2 It is presently not clear which of these hepatocyte proteins is (are) critical to host defense against LPS and TNF lethality. Nevertheless, from the identity and effectiveness of the more than 70 agents that have been shown to protect against lethality in the D-galN model (see below), insight may conceivably be gained.
The complete protection afforded by one of the first of these protective agents to be reported, namely neutralizing antibody against TNF, would predict that the scope of the D-galN model could conceivably extend beyond LPS to any bacterial component that stimulates the host to produce TNF. 2 Indeed, in the years that have followed, D-galN has been found to sensitize mice, among other animal species, to the lethal effects of superantigens, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] bacterial lipoprotein and lipopeptides, [26] [27] [28] bacterial (CpG) DNA, [29] [30] [31] [32] as well as to the Gram-negative and Gram-positive bacteria from which they are derived. [33] [34] [35] [36] [37] [38] 
REVIEW

Mechanisms of LPS lethality in normal versus D-galNsensitized mice
In assessing protection against lethality, an initial test for protection for any given agent is typically made at or near the LD 50 . With the D-galN-sensitized model of LPS lethality, that would mean an LPS dose of 0.001-0.005 µg in mice, 1 whereas for corresponding unsensitized LPS lethality in mice, an LPS dose of approximately 200 µg LPS would be anticipated. Focusing strictly on protection at the LD 50 , however, does require comment. For example (as shown in Table 1 ), hydrazine sulfate pretreatment can protect normal mice (i.e. not sensitized with D-galN), against LPS lethality. Thus, at an LPS dose of 200 µg, which was the experimentally determined LD 50 , hydrazine sulfate was able to dramatically reduce the number of deaths, from 12/24 to 0/16. Nevertheless, just a 25% increase in LPS (i.e. to a dose of 250 µg LPS) provided a quite different picture, with the same hydrazine sulfate pretreatment reducing deaths from 16/20 (80%) to 12/24 (50%). Thus, protection was 100% at the LD 50 , but much less at an LPS dose only one-fourth higher. 39 Moreover, the extent of lethality with hydrazine sulfate against 300 µg LPS was no different than lethality in the absence of the hydrazine sulfate but against an LPS dose of 250 µg LPS (Table 1) . 39 Similarly, against 250 µg LPS with hydrazine sulfate, as against 200 µg LPS without the hydrazine sulfate pretreatment. By contrast, the same hydrazine sulfate treatment also protected D-galN-sensitized mice LPS against lethality, but here protection remained 100% even at an LPS dose 10,000-fold greater than the LD 50 . 40 In both models, normal and D-galN-sensitized, protection was statistically significant at the LD 50 , indeed complete, yet the differences at higher LPS illustrate the additional perspective of comparing protection not only at the LD 50 , but also at higher LPS dosage.
Uridine protection against LPS was demonstrated at LPS doses as high as 100 µg in the D-galN model, whereas in the absence of added uridine, 0.01 µg LPS was lethal to all mice. The degree of uridine protection only began to diminish when the LPS LD 50 for mice not treated with D-galN (i.e. normal mice) was approached. Uridine offers no protection to such mice, and thus its ability to protect appears to be exclusively associated with the D-galN lethality model. 41 Marino et al. 42 compared wild-type mice with TNF knockout (-/-) mice with regard to lethal sensitivity to LPS in the D-galN model at low-and high-dose LPS. With 0.01 µg LPS, as might be expected, no wild-type mice survived. Nevertheless, with TNF-/-mice, even at 100 µg LPS, but under otherwise the same conditions of the D-galN model (20 mg/mouse), there were no deaths. 42 These gene knockout studies add further confirmation of the critical role of TNF for lethality in this model. It has also been shown, by contrast, that ICE-/and IL-/-mice are no less (or more) susceptible to the lethal effects of LPS in the D-galN model than are wildtype mice. 43 TNF is critical to lethality in the model, whereas IL-1 is evidently without effect. Finally, mice that are genetically transformed to produce high levels of soluble TNF-R1 are protected against LPS lethality in the D-galN model. 44 These results underscore the fact that the D-galN model of LPS lethality may be viewed as a lethal TNF sensitization model, and exclusively so up to an LPS dose of at least 100 µg. But what about higher LPS doses where LPS is lethal even in the absence of D-galN? Lethality with each of two possible TNF receptor double knockout mice, TNFR1 (p55)-/-and TNFR2 (p75)-/-, was tested independently. 45, 46 Only with the TNFR1-/knockout mice could D-galN-sensitized lethality be blocked. At high doses of LPS (300-1200 µg), lethality became manifest regardless of the status of TNFR1 or TNFR2. Such findings suggest that in normal mouse lethality models, and depending on the specific circumstances, other mechanisms beyond that of TNF-mediated lethality may also be involved. It is interesting that adenovirus-mediated blockade of TNF in mice protects against 100 µg LPS lethality in the D-galN model, but nevertheless does not prevent LPS from exerting detrimental effects on pulmonary host defense. 47 Studies relating to leukocyte adhesion further indicate that the lethal mechanisms operating at high LPS doses may involve mediating aspects quite distinct from those at low LPS doses in the D-galN model. In this regard, there have been a number of studies utilizing the D-galN model to explore inflammatory aspects of cell adhesion in the vascular system. These include, among others, investigations relating to ICAM-1, VCAM-1, PECAM-1 (CD31), selectin, P-selectin, and ET-1. 48-57 ICAM-1 does not influence TNF production, and, accordingly, ICAM-1-/-knockout mice exhibit lethal sensitivity to LPS in the D-galN model. By contrast, this same genetic deficiency of ICAM-1 does, nevertheless, protect against the lethal effects of high dose LPS (40 mg/kg). 48 A still different effect of LPS dose is seen in the influence of the protein kinase C activator phorbol-12-myristate-13-acetate (PMA) on LPS lethality in D-galN treated mice in comparison to normal unsensitized mice. PMA, with a 5-h pretreatment period, protects against LPS lethality in the D-galN model. This protection correlates well with corresponding attenuation in circulating levels of TNF. In the normal mouse model (i.e. in the absence of D-galN), the magnitude, and even the direction of, the PMA effect on lethality was found to be dependent on LPS dose. At 100 µg and 200 µg LPS, PMA pretreatment significantly increased lethality, whereas at 300 µg and 400 µg LPS, PMA was able to confer a modest measure of protection. With respect to the serum levels of TNF seen at these higher LPS doses, the attenuation of TNF with 100 µg LPS remained striking and similar to that from 400 µg LPS, despite the opposing effects of PMA on lethality at each of these LPS doses. Thus, it is reasonable to conclude that attenuation of TNF levels will result in protection in the D-galN model, but that, again, the situation in the normal mouse is not that sharply delineated. 58 Differences in LPS structure can also result in differences in lethality comparisons. S-LPS has an appreciably lower LD 50 in the D-galN model than does Ra-LPS, yet both were found to exhibit the same, higher, LD 50 in the normal mouse model. 59 Lethal challenge from bacteria, multiple bacterial components: additional mechanistic considerations Thus far, considerations of bacterial components as challenging agents in the D-galN model have been limited almost exclusively to challenge from endotoxin. In that regard, it had been emphasized that unlike normal mice, TNF-mediation is an absolute requirement for lethality in the D-galN model. Also emphasized was the requirement of endotoxin-responsive macrophages for a lethal response to LPS in the D-galN model, as is also true for early endotoxin tolerance in that model. 2, 5, 6 Moreover, the fact that D-galN also sensitizes to the lethal effects of exogenous TNF suggests that TNF produced by the host by whatever stimulating mechanism could conceivably result in a lethal response -provided the release of that TNF occurred in a timely manner (i.e. before the D-galN sensitizing power had become dissipated). 2 In this section, we examine the documented application of the D-galN lethality model to challenge from a number of bacterial components beyond LPS, including, among others, Staphylococcus aureus enterotoxin B (SEB), toxic shock syndrome toxin-1 (TSST-1), lipoprotein bound to peptidoglycan, and bacterial (CpG) DNA. This is followed by studies with live and killed Gram-positive and Gram-negative bacteria, again within the framework of D-galN-sensitization resulting in a lethal response. D-galN has been shown to dramatically sensitize to the lethal effects of heat-killed Gram-negative bacteria (Salmonella abortus equi and Salmonella typhimurium) and also to heat-killed Gram-positive bacteria (Staph. aureus, Propionibacterium acnes and Mycobacterium phlei). 33 In each instance, the bacteria elicited the release of TNF from host macrophages, and, in each instance, anti-TNF-α antiserum was able to fully protect against lethality, confirming that sensitization had resulted from the ability of each of the bacteria to stimulate host production of TNF, as with LPS stimulation of TNF release. Unlike with LPS, however, sensitization to lethality occurred not only in endotoxin responsive mice (C57BL/10ScN and C3H/HeN) but also in endotoxin non-responsive mice (C57BL/10 and C3H/HeJ), albeit larger amounts of Gram-negative bacteria were required. These findings indicate that although each of these bacteria sensitizes to lethality in one sense by a common mechanism (i.e. TNF-mediated lethality), fundamental differences in mechanism must be considered.
A number of laboratories have subsequently reported that D-galN also increases lethal sensitivity to Staph. aureus superantigen enterotoxin B (SEB). TNF is released into the circulation following challenge. 18, 19, 21, 22, 24, 60 Also, protection was conferred by anti-TNF-α 60 and by anti-TNFα/β neutralizing monoclonal antibody. 18, 24 Further, sensitization to SEB lethality was evident in mice regardless of their ability to respond to LPS at the level of the macrophage, including, among other mouse strains, in C3H/HeJ mice. 21, 24 Moreover, there are a number of lines of evidence to indicate that the generation of the TNF responsible for D-galN-sensitized SEB lethality derives, at least in part, from T-cell stimulation. SEB stimulates TNF release from splenic lymphocytes. Further, it stimulates TNF release with equal effectiveness in C3H/HeJ and C3H/HeN mice. 21 Also, the release of TNF into the circulation resulting from SEB challenge is followed almost immediately by the release of IL-2, 19, 21, 24 and subsequently by the release of IFN-γ. 18, 21, 24 Still additional evidence of T-cell involvement in D-galN-sensitized SEB lethality derives from T-cell depletion/replenishment experiments. SCID mice are T-cell deprived and are resistant to SEB lethality, whereas D-galN-sensitized SEB lethality returns upon T-cell replenishment. Mice that are otherwise sensitive to SEB lethality in the D-galN model are protected by cyclosporin A. 24 Thus, while TNF remains an absolute requirement for D-galN-sensitized lethality, the mechanism by which that TNF arises does not appear to be critical. An increase in TNF may well be derived, in some instances, from one or more cell types, T-cell or macrophage, depending on the challenging agent.
Other comparisons between SEB and LPS lethality in the D-galN model are also to be noted. Mice 5-8 weeks old are often more resistant than older mice to lethality in the D-galN model. 26 Among neonates, paradoxically, and by mechanisms not yet clarified, there was reported to be a greater sensitivity to LPS lethality in the D-galN model, but, conversely, a greater resistance to SEB. 60 A property analogous to early endotoxin tolerance, at least from a kinetic perspective, appears to be associated with SEB. Pretreatment with SEB 4 h prior to challenge with a second dose of SEB, but this second time plus D-galN, confers protection against lethality. 19 In that same study, the ability of SEB pretreatment to protect was also found against an otherwise lethal challenge from toxic shock syndrome toxin (TSST-1) plus D-galN. During the pretreatment period, a T-cell derived peak in TNF appears, and then diminishes, whereas the peak that would otherwise appear following SEB challenge is not seen following the second SEB dose plus D-galN. The SEB pretreatment did not, however, block the appearance of a serum TNF peak following subsequent challenge with LPS plus D-galN. Finally, it should be noted that another Gram-positive bacterial component, namely lipoteichoic acid, exhibited cross-tolerance with LPS when examined in normal mice. This cross-tolerance occurred at the level of the macrophage, with the suggested involvement of different Toll-like receptors, including TLR2 and TLR4. 61 From the above, it would appear that SEB and LPS are likely to exhibit 'early' tolerance independently, in terms of target cells (macrophage or T-cell). It would also seem at least possible that synergy may develop at some level in terms of host response to distinctive external challenges. With respect to SEB and LPS, it has been shown that when SEB and LPS are administered together, the doses that are lethal individually can be reduced 100fold and still be lethal. 22 Such synergy was evident in both normal and D-galN-sensitized mice and could be blocked by administration of cyclosporin A and also by anti-IFN-γ mAb. In another study, it was reported that SEB was not lethal to mice even with 20 mg/mouse D-galN, but that its lethality was potentiated in these mice upon addition of LPS. 20 In the same study, however, an LPS dose as high as 0.1 µg plus 20 mg D-galN was still only marginally lethal (3/11) to endotoxin-responsive (C3HeB/FeJ) mice. Synergistic host responses have also been reported with other bacterial components in normal and/or D-galN-sensitized mice. 27, 30, [62] [63] [64] [65] [66] [67] With one such bacterial combination, namely lipoprotein and LPS, a synergistic capacity to induce lethal shock was demonstrated with D-galN-sensitization even in C3H/HeJ mice. 27 LPS, as would be expected, was unable to stimulate C3H/HeJ macrophages to release TNF, but did potentiate lipoprotein stimulation of these same macrophages to do so, in accordance with its synergistic (or potentiating) effect on lethality in the D-galN-sensitized mice.
Warren and co-workers have investigated the possibility that peptidoglycan-associated lipoprotein (PAL) may be released during sepsis and subsequently contribute to bacterial virulence and inflammation. 26 Using the cecal ligation and puncture model, they were able to show that: (i) PAL was released into the circulation; (ii) purified PAL was lethal to C3H/HeJ mice in the D-galN model; and (iii) challenge with PAL mutant bacteria was less lethal to C3H/HeN mice than challenge with corresponding PAL-containing wild-type bacteria. Importantly, the D-galN model was valuable in allowing these workers to demonstrate directly a lethal effect of PAL as one piece of evidence, among others, in support of their fundamental hypothesis.
The importance of LPS release from Gram-negative bacteria on pathogenesis in sepsis lethality continues to be a subject of considerable interest, in particular, with respect to the impact of antibiotic treatments. 68 Within that framework, the D-galN lethality model has proven to be useful, most notably in comparing effects of different β-lactam antibiotics including, among others, imipenem versus ceftazidime in otherwise normal and also leukopenic mice. [69] [70] [71] The mechanism of lethality in the D-galN model of challenge from TSST-1, another superantigen from Staph. aureus, bears similarities to that from SEB. Anti-TNF-α/β neutralizing monoclonal antibody protected against lethality. Further, TNF production appears to be Tcell mediated, as evidenced by similar experiments discussed above with SCID mice, and TCA repopulation, along with protection by cyclosporin A under conditions where TSST-1 would otherwise be lethal in D-galN-sensitized mice. 24 Studies with purified cell walls from heatkilled Streptococcus mitis have demonstrated TNF release from whole blood of both endotoxin-responsive (OF1) and endotoxin-resistant (C3H/HeJ) mice. Anti-TNF-α neutralizing antibody gave complete protection against D-galNsensitized lethality to both these strains of mice. 72 As noted by the authors of that report, these studies offer still additional confirmation of the earlier findings with heat-killed Gram-positive bacteria demonstrating the absolute importance of TNF to D-galN-sensitized lethality. 33 Gram-positive or Gram-negative bacterial DNA is lethal to D-galN-sensitized mice. 29 The associated properties are, in each instance, consistent mechanistically with what has been reviewed above with respect to TNF mediation, and macrophage versus T-cell involvement in D-galN-sensitized lethality. The ultimately lethal response, which is associated with CpG motifs, is also associated with an early TNF peak, similar in kinetics of appearance to that from LPS. Unlike, however, with LPS, bacterial DNA stimulates the release of TNF from C3H/HeJ peritoneal macrophages in vitro. Mice lacking the TNF receptor p55 or pretreated with anti-TNF-α monoclonal antibody were protected. Finally, SCID mice, lacking T-cells, also were killed by the bacterial DNA in the D-galN-sensitized mice. 29, 30, 32 A comparison between live Escherichia coli and live Staph. aureus lethality in the D-galN model revealed a number of fundamental differences. 34 With E. coli, the results were consistent with what would be predicted by LPS being the major bacterial component contributing to lethality. The magnitude of D-galN-sensitized lethality, the serum TNF profile, and the loss of dexamethasone protection in C3H/HeJ mice versus CF-1 mice were all consistent with a dominant LPS effect. Similar comparisons with several additional Gram-negative clinical or laboratory isolates led to the same conclusion. 38 The ability of D-galN to increase lethality from live Staph. aureus was only marginal, notwithstanding the D-galNsensitized lethality seen with heat-killed Staph. aureus, or with individual Gram-positive bacterial components, as discussed above. Conceivably, the possible impact of one or more such components remains only latent in these live bacteria. Such a possibility is strengthened by the dramatic effect of a potent antibiotic (imipenem) administered at the time of challenge. 35, 36 The kinetics of TNF release are shifted to earlier times, within the kinetic range where D-galN-sensitized lethality would be anticipated. Accordingly, the effectiveness of antibiotic protection becomes markedly reduced in D-galN-treated mice, compared with normal mice. 35 By contrast, dexamethasone protection is now potentiated following antibiotic treatment in the D-galN model, both among CF-1 mice and C3H/HeJ mice. 36 Given the Gram-negative and Gram-positive bacterial components that contribute to lethality in D-galN-sensitized mice, it will be of some interest to know the impact of antibiotic killing on the ability of other agents, extrapolating from dexamethasone, to protect against lethality.
In summary, application of the D-galN-lethality model has supported the concept that a number of bacterial components, including and beyond endotoxin, can contribute to, or result in, TNF-mediated lethality. Moreover, release of one or more such components in vivo is an important consideration -both in terms of lethal consequences and also corresponding potential modes of protection as, for example, was noted above with dexamethasone and which is further discussed below. Studies with bacterial components beyond endotoxin have also helped broaden the scope as to where TNF is released as a component of sepsis pathophysiology, to include the T-cell as an important source of TNF release in sepsis. This is of potential consequence when other bacterial components are implicated, both from Gram-positive and Gram-negative bacteria. Finally, endotoxin-stimulated release of TNF from the macrophage, coupled with other bacterial component-stimulated release of TNF, including from the T-cell, would appear to be consistent with synergistic manifestations between LPS and other bacterial components that have emerged upon application of the D-galNlethality model.
Protecting agents
There are at least 70 agents that have been reported to confer protection when given prior to or, in a very few instances, at the same time as what would otherwise be a lethal dose of LPS plus D-galN and/or TNF plus D-galN. One example of such a protecting agent is LPS itself, administered shortly before challenge, i.e. early endotoxin tolerance (in contrast to late endotoxin tolerance, which results from an adaptive rather than an innate immune response). In both normal and D-galN-sensitized mice, the LPS pretreatment takes place in the absence of D-galN. Attenuation of the TNF response is, of itself, not sufficient for early endotoxin tolerance in a normal mouse model. Attenuation of the TNF response is, however, both sufficient and necessary for early endotoxin tolerance in the D-galN model. 8 Thus, TNF is again seen to be critical to lethality in the D-galN model.
Early endotoxin tolerance in the D-galN model includes cross-tolerance between TNF and LPS (i.e. pretreatment with TNF protects against LPS and vice versa). 4 A question related to cross tolerance is that of commonality in cross signaling. Recent studies of cross tolerance between macrophage-activating lipopeptide 2 (MALP-2) and LPS in the D-galN model of LPS and TNF lethality suggest the involvement of TLR2, TLR4, and TLR6 in the signaling leading to tolerance. 73 As with normal mouse models of LPS lethality, studies with the genetically LPS hyporesponsive C3H/HeJ and C57BL/10ScCr mouse strains have proved to be invaluable, particularly when coupled with adoptive transfer studies with macrophages isolated from LPS responsive mice. This development includes, but is not limited to, studies into the mechanism of early endotoxin tolerance. LPS-responsive macrophages are essential to LPS lethality as well as to early endotoxin tolerance in the D-galN model. 2, 3, 5, 6, 74 One concern should be noted with respect to early endotoxin tolerance in relationship to other modes of pretreatment that result in protection against subsequent lethal challenge. There remains the commonly recognized possibility of artifacts arising due to endotoxin contamination, not only during challenge, but also during pretreatment. (In general, the author notes that particular care was taken to avoid such problems in the papers cited in this review.) Pretreatment of endotoxin-responsive macrophages in vitro with either dexamethasone or LPS established that dexamethasone protection against LPS in the D-galN α 1 -Acid glycoprotein Anti-CD28 Ab Anti-idiotype Ab mimicking LPS inner-core (Mab4G2) Anti-Klebsiella pneumoniae mAbs* Anti-LBP Ab Anti-lipid A mAb (MLA-1) Anti-LPS mAbs (SDZ 219-800, WN1222-5, D6B3, D6B4) Anti-LPS 80-kDa binding protein mAb Anti-platelet Ab Anti-TNF antiserum or mAb α 1 -Antitrypsin Table 2 . Agents that protect against LPS and/or TNF in the D-galN lethality model model also occurs at the level of the macrophage. 3 Inasmuch as dexamethasone was shown, in the same study, to be ineffective against lethal challenge from TNF, its protection against LPS is likely to occur at the level of TNF production or earlier, 3 as is also true for the normal mouse model. 75 Possible involvement of endogenous glucocorticoids in early endotoxin tolerance was tested following disruption of the pituitary/adrenal axis of glucocorticoid production as a consequence of either hypophysectomy or adrenalectomy. Among either adrenalectomized or hypophysectomized mice, the ability of a 90-min pretreatment with 0.02 µg LPS to protect against subsequent challenge with 0.01 µg LPS and 20 mg D-galN could still be demonstrated 8 h after challenge, but the protection, unlike with normal or sham-operated mice, could not be sustained. Endogenous glucocorticoid appears, therefore, to be necessary, but not sufficient, for sustained early endotoxin tolerance. 76 Evans and Zuckerman had earlier also provided evidence for the existence of both glucocorticoid-independent and glucocorticoid-dependent mechanisms of tolerance. 77 Other protecting agents, in addition to LPS in early endotoxin tolerance, and that also protect against LPS and/or exogenous TNF in the D-galN lethality model are listed alphabetically in Table 2 . These same agents are also provided in the text below with additional comments, where appropriate, with respect to animal model, time of administration relative to that challenge, and D-galN dose. There is also one instance where protection is against monophosphoryl lipid A. In the absence of additional comments in the text, or noted in Table 2 , for a given protecting agent, the reader should assume that: (i) the animal model is the mouse; (ii) the protecting agent is administered prior to challenge; and (iii) that the D-galN dose is at least 10 mg/mouse. It should be emphasized that the recommended D-galN dose is 20 mg/mouse. 8 Where protection has also been demonstrated against bacteria and/or non-LPS bacterial components it is noted in the text, with the identity of the corresponding challenging agent(s) provided. These protecting agents, with the corresponding additional challenging agent(s), are again listed in Table 3 .
The complete overall list, with additional comments, follows (again in alphabetical order): α 1 -acid glycoprotein; [78] [79] [80] anti-CD28 Ab (also challenge from Staph. aureus enterotoxin B); 81 anti-idiotype Ab mimicking LPS inner-core (MAb4G2); 82 anti-Klebsiella pneumoniae mAbs (D-galN, 8 mg/mouse; also challenge from K. pneumoniae O1:K2); 83 anti-LBP Ab; 84 anti-lipid A mAb (MLA-1); 85 anti-LPS mAbs (SDZ 219-800, WN1 222-5, D6B3, D6B4) (D-galN, 8 mg/mouse 73 ); 86, 87 anti-LPS 80 kDa binding protein mAb; 88 anti-platelet Ab; 89 anti-TNF antiserum or mAb; 3, 8, 33, 90, 91 (also challenge from Gram-positive and Gram-negative bacteria); 33 (also monkey model; D-galN, 15 min prior to challenge; post-treatment [15 min]); 90 α 1 -antitrypsin; 92 cationic antimicrobial protein (CAP-18) derived peptide (also Pseudomonas aeruginosa); 93 a cathelicidin antimicrobial peptide (LL-37/hCAP-18); 94 CD14 antisense oligonucleotide (SM 0105A); 95 cepharanthin; 96 clindamycin; 97 colchicine; 98 C-reactive protein; 99 CuII (diisopropyl salicylate) 2 100 (protection against monophosphoryl lipid A), cycloheximide; 101 deferoxamine (D-galN, 1 h prior to challenge); 102 dehydroepiandosterone; 103 dexamethasone; 3,76,104-106 (co-treatment and post-treatment of same animals); 106 (against challenge from live versus antibiotic-killed Gram-positive and Gramnegative bacteria); [34] [35] [36] 76 diethylcarbamazine (co-treatment and post-treatment of same animals); 106 ebselen (also rat D-Galactosamine lethality model: scope and limitations 153 151 3-substituted 2-oxo-1,4 thiazines; 152 turpentine; 153 tyrphostin AG-556 (rat model, co-treatment, also challenge from group B streptococcus); 154 uridine (co-treatment; post-treatment); 1,2,41 WEB2170; 79 wogonin. 110 Most of the above protecting agents, with very few exceptions, must evidently be given prior to challenge in order to be effective. A few can be given at the same time as challenge, or up to 15 min into the challenge. Uridine is a singular exception in that it is completely protective against LPS and TNF when given as late as 2 h into challenge, 1,2,41 and even partially protective when first administered 3-h post-challenge. 1 This should be viewed in light of the particularly acute kinetics of the D-galN lethality model, with death occurring as early as 5 h into challenge, and with even more acute first outward appearance of symptoms. 1 The kinetic properties of uridine protection are consistent with our basic understanding of the D-galN model. 13 By 3-h following administration of D-galN, it has been documented that UTP levels deplete by about 90%, and that uridine administration at that time will bring UTP back to at least normal levels within an hour. 13 The ability of D-galN to rapidly deplete UTP levels, and consequently liver RNA and protein synthesis, suggests that one or more of such proteins may be extremely critical to host defense against lethality in the model. The fact that several of the proteins shown to protect are acute-phase proteins (see above) is consistent with such a possibility, yet there is no clear indication that any one of these is, of itself, particularly critical to host defense. This may conceivably be a consequence of multiple proteins being important to protection under the umbrella of uridine protective efficacy. In addition, pre-induction of an acute-phase response need not, of itself, confer protection. In that regard, IL-6 pretreatment, as confirmed by subsequent increases in circulating fibrinogen and C3, was found to be unable to protect in both the D-galN and normal mouse models of LPS lethality. 155 Recently, Qureshi et al. 125 demonstrated a link between the D-galN LPS lethality model and the proteasome. In particular, it was shown that the proteasome inhibitor, lactacystin, protected D-galN-sensitized mice against ReLPS lethality, and also blocked the expression of TLR2 mRNA. 125 In this regard, it has also been reported that LPS or TNF, each in combination with D-galN, inhibited the constitutive expression of several heat-shock proteins (hsp70, hsp60, hsp32, hsp25) and the inducible expression of hsp70. Administration of anti-TNF neutralizing antibody not only prevented the reduced expression of constitutive hsp70, but actually increased its inducible expression. 156 Conceivably, sensitization in the D-galN model relates not only to changes in protein synthesis during the early period of lethal endotoxin shock, but also to concomitant changes in protein inactivation and degradation.
Hydrazine sulfate protection against LPS and TNF lethality in the D-galN model is consistent with a link between D-galN sensitization, modulation of the (potential) acute phase protein and gluconeogenic regulatory enzyme phosphoenolpyruvate carboxykinase, and glucose homeostasis. McCallum and coworkers had earlier established in normal mice that LPS induces a significant increase (34%) in circulating glucose levels by 2 h into challenge which then reverses to an overall marked decrease (55%) by 6 h, attributable, at least in part, to a possible antagonism to the action of gluconeogenic hormones. [157] [158] [159] More recently, Topaloglu et al. 160 have also confirmed a significant hyperglycemia (approximately 7 mM) at 2 h in 10-day-old rats challenged with only 0.01 mg/kg LPS. Nevertheless, when D-galN was included in the challenge, not only was the hyperglycemia not observed at the 2 h time point, but rather a highly significant severe hypoglycemia to approximately 1 mM became evident. 160 Although hydrazine sulfate was tested and found unable to alter such severe hypoglycemia, it was proposed that its ineffectiveness might conceivably be a consequence of an immature pituitary/adrenal axis in such young animals. 161 It had earlier been established that an intact pituitary/adrenal axis is essential for hydrazine protection. 40, 115 Also, young rodents might well be expected to lack the usual sensitivity to D-galN seen in older animals. 8 It has long been recognized that hydrazine is itself hypoglycemic. 162 Ray et al. showed that the hypoglycemia from hydrazine treatment arose from a metabolic crossover at the reaction catalyzed by phosphoenolpyruvate carboxykinase (PEPCK) and that this crossover was followed by continuing increase in isolated liver PEPCK activity through the next 5 h. 163 The optimum hydrazine pretreatment time for protection against LPS or TNF is 5 h. 39, 40 Viewed from that perspective, such a time frame allows for an increase in hepatic PEPCK until the time of challenge in the D-galN model, possibly offsetting a marked decrease in PEPCK synthesis that would otherwise be expected to result from the D-galN treatment.
It, therefore, remains a possibility that part of D-galN sensitization may result from severe impairment in the ability of the host to mount an effective gluconeogenic response during the period immediately following D-galN administration. Nevertheless, given the myriad of agents that protect in the model, it is likely that a number of acute-phase proteins and other agents contribute to protection by a variety of mechanisms. These protective agents -with the obvious exceptions of anti-TNF neutralizing antibody and, in a sense, uridine -have yet to be fully delineated in terms of specific mechanism(s) of completely overcoming the remarkable host sensitivity to D-galN. Finally, even with uridine, it remains unclear which specific RNAs and/or proteins are most critical to its protective efficacy.
Implications of TNF-mediated lethality toward varied routes to protection: studies with dexamethasone and α 1 -antitrypsin
D-GalN-sensitized lethality resulting from challenge by one or more bacterial components is, as discussed above, TNFmediated. Any agent that interferes with (i) the production of TNF or (ii) TNF-mediated lethality might conceivably protect. Moreover, agents that interfere with (ii) may conceivably protect regardless of the route leading to the stimulation of TNF production, i.e. the nature of the bacterial component(s) challenging the host. This, by contrast, would not necessarily be expected if protection occured only through action at the level of TNF production.
Glucocorticoids can be considered as potentially beneficial within such a context, although glucocorticoids have long remained controversial in terms of effectiveness against bacterial sepsis. 36, 164 An early and critical finding in that development was the discovery that dexamethasone down-regulates LPS-stimulated TNF production at the level of the macrophage. 3, 75 Nevertheless, dexamethasone is unable to protect against the lethal actions of exogenous TNF, even within the D-galN lethality model (see above). 3 The ability of dexamethasone to protect D-galN-sensitized (and unsensitized) mice against endotoxin lethality extends to proliferating Gram-negative bacteria, both as seen from dexamethasone protection against each of several Gramnegative bacteria in outbred (CF-1) mice and by the corresponding lack of protection against these same bacteria in endotoxin hyporesponsive (C3H/HeJ) mice. 34, 38 D-GalN-sensitization, as discussed above, is not unique to endotoxin nor, by extension, to Gram-negative bacteria; nor is this also true of dexamethasone protection against corresponding lethal challenge. D-GalN sensitizes to the lethal effects of proliferating enterococcal strains (Grampositive), and dexamethasone correspondingly protects. 38 These properties appear, however, to be exceptional to enterococcal strains (E. faecalis, E. faecium) upon comparison with other Gram-positive bacterial proliferating bacteria. Tests with several proliferating staphylococcal and streptococcal isolates demonstrate that D-galN neither sensitizes to lethality, nor does dexamethasone protect. 38 This whole picture, importantly, changes upon bacterial killing. 33 Dexamethasone does, in fact, protect against imipenem-killed Staph. aureus, and with equal effectiveness in both outbred (CF-1) and endotoxin hyporesponsive (C3H/HeJ) mice. 35, 36 Moreover, dexamethasone protects against imipenem-killed E. coli in CF-1 mice and also in the endotoxin hyporesponsive C3H/HeJ mice. 35, 36 Accordingly, it would be premature to conclude that D-galN-sensitized lethality, and corresponding dexamethasone protection, is necessarily restricted to bacterial endotoxin content, even among Gram-negative bacteria, and may also depend critically on the identity of the bacterial organism, whether live or killed.
A quite different situation in terms of routes to protection is presented by the acute-phase protein α 1 -antitrypsin (α 1 -AT). Unlike the case with dexamethasone, α 1 -AT does protect D-galN-sensitized mice by acting directly against the lethal effects of TNF. 92 As a neutrophil elastase inhibitor, it is beneficial against emphysema, with individuals defective in the corresponding gene being highly susceptible to that disease. Using D-galN to bring about a deficiency in α 1 -AT, a short-term experimental animal emphysema model has been developed. 165, 166 Fiers and co-workers have reported that platelet-activating factor is a mediator of TNF lethality in D-galN-sensitized mice and have suggested that interference with platelet aggregation may be important to the protective efficacy against TNF of both α 1 -AT and α 1 -acid glycoprotein in D-galN-sensitized animals. [78] [79] [80] 92 
D-galN-sensitized lethality as a test for in vivo endotoxicity
Caution must be exercised in concluding that D-galN-sensitized lethality attributable to Gram-negative bacteria is, in all circumstances, endotoxin-derived, as discussed above. In contrast, challenge with purified LPS or its various derivatives, by definition, presents no such concern. In that regard, the question has been raised as to the relationship between endotoxicity and structural differences among different LPS, particularly given the clinical discrepancy between serum endotoxin levels and mortality resulting from Gram-negative sepsis. Recently, a careful comparison was made between LPS purified individually from 8 different Gram-negative bacterial isolates. 167 These purified LPSs differed in their overall weight, phosphate content, and 2-keto-3-deoxyoctonate content. Differences between these LPSs proved insignificant whether the Limulus amoebocyte lysate assay was utilized as a measure of endotoxicity 168, 169 or D-galN-sensitized lethality. 1 Lipid A has long been recognized as being a large moiety within the endotoxin molecule that is fundamentally responsible for its lethality. 170, 171 (A graduate student, named Ernst Rietschel, rushed into a crowded Freiburg restaurant to proclaim to his colleague and friend 'Die Mäuse sind tot!' [C. Galanos, personal communication] .) Further, its structure has since been fully elucidated. 172 As a consequence of these developments, there has been considerably increased interest in lipid A, lipid A analogs, and lipid A derivatives. In such studies, the D-galN lethality model has been routinely used, in concert with other measures to test for endotoxicity and to test, in particular, for lethal toxicity. In one such study, sensitized lethality in the D-galN model and sensitized lethality as a consequence of partial hepatectomy were both used as a lethality test, with similarly positive results in each instance. 193 D-galNsensitization is by no means the only vehicle to induce hypersensitivity to LPS lethality. Nevertheless, it has been the sensitization model used almost exclusively to test for lipid A lethality, as well as remaining of active interest as a general means to sensitize to TNF lethality. CONCLUSIONS D-galN-sensitized lethality is fundamentally a means to amplify the lethal effects of TNF, whether by stimulation of the macrophage and/or the T-cell. Stimulation by endotoxin is perhaps the most dramatic and best studied, with more than 70 agents shown to protect against LPS and/or TNF. Nevertheless, other bacterial components in addition to LPS have been shown to exhibit D-galN-sensitized lethality, as well as whole bacteria, live or killed. These continuing developments add still more to interest in the model, and within such an extended framework, an increasingly systematic development of therapeutic intervention strategies would seem to be conceivable. It should nevertheless be acknowledged that while TNFsensitized lethality may not be an ideal model for an immunocompromised host, even within an animal experimental setting, neither is the healthy, normal animal. The fact that the broad impact of D-galN on hepatocyte RNA and protein synthesis translates into sensitization to a single cytokine, regardless of the nature of the challenging agent or the mechanism of host stimulation, is truly remarkable, particularly given the multitude of mediators that have been implicated in sepsis. 198 This remarkable 'gift of nature' (C. Galanos) has not only been invaluable in the study of experimental sepsis but, conceivably, may mimic the human condition in ways yet to be elucidated.
